LONDON, April 24, 2025 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) announced today that it will host a conference call and live webcast on Tuesday, April 29, 2025 at 8:30 a.m. Eastern Time to report its first quarter 2025 financial results and recent portfolio execution. A live webcast will be accessible through the Investors & Media section of the company’s website at www.kiniksa.com. Individuals interested in participating in the call via telephone may register here. Upon ...

Core Viewpoint - Ascendis Pharma A/S will report its first quarter 2025 financial results and provide a business update on May 1, 2025, after U.S. market close, followed by a conference call and live webcast [1] Company Overview - Ascendis Pharma is a global biopharmaceutical company focused on its innovative TransCon technology platform to develop new therapies addressing unmet medical needs [3] - The company is headquartered in Copenhagen, Denmark, with additional facilities in Europe and the United States [3] Event Details - The live webcast for the financial results will be accessible through a provided link, and a replay will be available for 30 days post-event [2]

Core Insights - Business First Bancshares, Inc. reported a net income of $19.2 million or $0.65 per diluted common share for the quarter ended March 31, 2025, reflecting an increase of $4.1 million and $0.14 compared to the previous quarter [1][42] - The company declared a quarterly preferred dividend of $18.75 per share and a common dividend of $0.14 per share, both to be paid on May 31, 2025 [2] Financial Performance - Core net income on a non-GAAP basis for the quarter was $19.3 million or $0.65 per diluted common share, a slight decrease of $0.2 million and $0.01 from the linked quarter [1] - Net interest income totaled $66.0 million, with a net interest margin of 3.68% and a net interest spread of 2.91%, compared to $65.7 million, 3.61%, and 2.77% for the previous quarter [7][14] - Return on average assets was 1.00% and return on common equity was 10.48% for the quarter, compared to 0.78% and 8.23% for the linked quarter [19][36] Loan and Deposit Trends - Loans held for investment remained flat with a slight decrease of $480,000 or 0.01% from the previous quarter, while real estate construction loans decreased by $36.8 million [5] - Deposits decreased by $53.1 million or 0.82%, primarily due to customer withdrawals, although new account openings generated approximately $379.9 million during the quarter [10] Credit Quality - The ratio of nonperforming loans increased by 27 basis points to 0.69% as of March 31, 2025, while nonperforming assets to total assets rose by 16 basis points to 0.55% [6][35] - The company recorded a provision for credit losses of $2.8 million, down from $6.7 million in the previous quarter [16] Capital and Equity - Common equity to total assets increased from 9.26% to 9.69%, and tangible common equity to tangible assets rose from 7.63% to 8.06% [7] - Book value per common share increased to $25.51 at March 31, 2025, compared to $24.62 at December 31, 2024 [12][36] Securities and Investments - The securities portfolio increased by $27.0 million or 3.02%, with positive fair value adjustments contributing $12.9 million to this increase [9] - Noninterest income increased by $1.4 million or 11.55%, driven by gains on loan sales and other income sources [17]

Core Viewpoint - Kiniksa Pharmaceuticals International, plc will host a conference call on April 29, 2025, to discuss its first quarter 2025 financial results and recent portfolio execution [1]. Group 1: Conference Call Details - The conference call is scheduled for April 29, 2025, at 8:30 a.m. Eastern Time [1]. - A live webcast will be available on the company's website, and participants can register for telephone access [2]. - A replay of the event will be accessible on Kiniksa's website approximately 48 hours after the call [2]. Group 2: Company Overview - Kiniksa is a biopharmaceutical company focused on developing therapies for debilitating diseases, particularly in cardiovascular indications [3]. - The company aims to discover, acquire, develop, and commercialize novel therapies for diseases with unmet needs [3]. - Kiniksa's portfolio is based on strong biological rationale and validated mechanisms, offering potential for differentiation in the market [3].

Comcast (CMCSA) reported first-quarter 2025 adjusted earnings of $1.09 per share, which beat the Zacks Consensus Estimate by 11.22% and increased 4.8% year over year.Consolidated revenues decreased 0.6% year over year to $29.88 billion. The figure beat the Zacks Consensus Estimate by 0.69%.Quarter Details of CMCSAConnectivity & Platforms revenues (67.4% of revenues) declined 0.7% year over year to $20.13 billion in the reported quarter. Under the segment, Residential Connectivity & Platforms revenues decrea ...

Tempus AI (TEM) has skyrocketed 21% in the last three days, fueled by news of a $200 million partnership with AstraZeneca (AZN) and Pathos AI. The multi-year deal focuses on building a multimodal AI-driven foundation model for oncology, using TempusAI’s de-identified oncology data. This partnership is a big win, matching Tempus AI’s fourth-quarter 2024 revenues alone.But with the stock on fire, the big question is, will the rally continue, or is Tempus AI already priced for perfection? Let’s take a closer l ...

Interpace Expects to Remain Profitable as a Thyroid-focused Business PARSIPPANY, NJ, April 24, 2025 (GLOBE NEWSWIRE) -- Interpace Diagnostics®, a subsidiary of Interpace Biosciences®, (“Interpace” or the “Company”) (OTCQX: IDXG) today announced that the Genetic Testing for Oncology (L39365) Local Coverage Determination (LCD) issued by the Medicare Administrative Contractor Novitas Solutions will go into effect, ending reimbursement for their PancraGEN® test. The Centers for Medicare & Medicaid Services (CMS ...

FREMONT, Calif., April 24, 2025 /PRNewswire/ -- Socket Mobile, Inc. (NASDAQ: SCKT), a leading provider of data capture and delivery solutions for enhanced workplace productivity, today reported financial results that are determined in accordance with generally accepted accounting principles in the United States ("GAAP") for the three months ended March 31, 2025.First Quarter 2025 Financial Highlights: Revenue of $4.0 million, reflecting a 20% decrease compared to $5.0 million for the prior year's quarter, ...

DENVER, April 24, 2025 (GLOBE NEWSWIRE) -- EverCommerce Inc. (NASDAQ: EVCM), a leading provider of SaaS solutions for service SMBs, will report its first quarter 2025 financial results after the U.S. financial markets close on Thursday, May 8, 2025. Management will host a conference call on Thursday, May 8 at 5:00 p.m. Eastern Time / 3:00 p.m. Mountain Time to discuss the Company’s financial results and provide a business update. Please visit the “Investor Relations” page of the Company’s website (https://i ...

ST. PETERSBURG, Fla., April 24, 2025 (GLOBE NEWSWIRE) -- BayFirst Financial Corp. (NASDAQ: BAFN) (“BayFirst” or the “Company”), parent company of BayFirst National Bank (the “Bank”) today reported a net loss of $0.3 million, or $0.17 per common share and diluted common share, for the first quarter of 2025, a decrease of 103.4% compared to $9.8 million, or $2.27 per common share or $2.11 per diluted common share, in the fourth quarter of 2024. “While we were encouraged by net interest margin expansion and st ...